It is possible that poziotinib’s increase in the efficacy of the chemotherapeutic drugs in the drug-resistant colon cancer cells could be due to downregulating the expression level of the ABCG2 and ABCB1 transporter protein. The gene discussed is ABCG2; the disease is colonic neoplasm.